A Phase 3 interventional study of ALKS 8700 and Dimethyl Fumarate in Relapsing Remitting Multiple Sclerosis, sponsored by Biogen. Completed at 67 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-07-14.
Sponsored by Biogen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen — none open to participants now, 1 under way, 1 of them phase 3. Multiple Sclerosis, Relapsing-Remitting · Biogen.
Among the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen, this one is the 14th largest by enrollment of the 59 interventional ones that give a count, is one of 5 that started in 2017, is one of 25 in phase 3, and was the 65th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 506 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 152 across the 59 interventional studies, 277 across the 19 observational. Of the 72 that completed or were terminated, 31 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
1 of the studies in Multiple Sclerosis, Relapsing-Remitting by Biogen that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03958877Phase 3BiogenA Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis | 2027-05-20 |
Add it to your calendar (.ics) → With an account.
Among the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objectives of this study are to evaluate the utility of two gastrointestinal (GI) symptom scales (Individual GI Symptom and Impact Scale {IGISIS} and Global GI Symptom and Impact Scale {GGISIS}) in assessing GI tolerability in adult subjects with RRMS after administration of ALKS 8700 or Dimethyl Fumarate (DMF) in Part A, to compare the GI tolerability of ALKS 8700 and DMF in adult subjects with RRMS using IGISIS and GGISIS in Part B, and to Evaluate the safety and tolerability of ALKS 8700 in adult subjects with RRMS in Parts A and B.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral capsules, administered orally twice daily.
Drug: ALKS 8700
Oral capsules, administered orally twice daily.
Drug: Dimethyl Fumarate
Administered as specified in the treatment arm.
Administered as specified in the treatment arm.
Also known as: Tecfidera
Number of Days With Any Individual Gastrointestinal Symptom and Impact Scale (IGISIS) Individual Symptom Intensity Score ≥2 Relative to Exposure Days in Parts A and B
IGISIS assessed the intensity of five individual GI symptoms: nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea. Participants rated the intensity of each individual symptom via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). IGISIS was completed by the participants using e-diaries.
Time frame: End of treatment (up to Week 6) for both Parts A and B
Number of Days With Any IGISIS Individual Symptom Intensity Score ≥2 Relative to Exposure Days in Part B
IGISIS assessed the intensity of five individual GI symptoms: nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea. Participants rated the intensity of each individual symptom via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). IGISIS was completed by the participants using e-diaries.
Time frame: End of treatment (up to Week 6) for Part B
Number of Days With Any IGISIS Individual Symptom Intensity Score ≥1 Relative to Exposure Days in Parts A and B
IGISIS assessed the intensity of five individual GI symptoms: nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea. Participants rated the intensity of each individual symptom via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). IGISIS was completed by the participants using e-diaries.
Time frame: End of treatment (up to Week 6) for both Parts A and B
Number of Days With Any IGISIS Individual Symptom Intensity Score ≥3 Relative to Exposure Days in Parts A and B
IGISIS assessed the intensity of five individual GI symptoms: nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea. Participants rated the intensity of each individual symptom via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). IGISIS was completed by the participants using e-diaries.
Time frame: End of treatment (up to Week 6) for both Parts A and B
Number of Days With a Global GI Symptom and Impact Scale (GGISIS) Symptom Intensity Score ≥1 Relative to Exposure Days in Parts A and B
GGISIS is a global scale to assess the overall intensity of GI symptoms (nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea). Participants rated the intensity of GI symptoms via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). GGISIS was completed by the participants using e-diaries.
Time frame: End of treatment (up to Week 6) for both Parts A and B
Number of Days With a GGISIS Symptom Intensity Score ≥2 Relative to Exposure Days in Parts A and B
GGISIS is a global scale to assess the overall intensity of GI symptoms (nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea). Participants rated the intensity of GI symptoms via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). GGISIS was completed by the participants using e-diaries.
Time frame: End of treatment (up to Week 6) for both Parts A and B
Number of Days With a GGISIS Symptom Intensity Score ≥3 Relative to Exposure Days in Parts A and B
GGISIS is a global scale to assess the overall intensity of GI symptoms (nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea). Participants rated the intensity of GI symptoms via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). GGISIS was completed by the participants using e-diaries.
Time frame: End of treatment (up to Week 6) for both Parts A and B
Worst IGISIS Individual Symptom Intensity Score During the 5-Week Treatment Period in Parts A and B
IGISIS assessed the intensity of five individual GI symptoms: nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea. Participants rated the intensity of each individual symptom via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). IGISIS was completed by the participants using e-diaries. Scores were averaged for 5-week treatment period.
Time frame: End of treatment (up to Week 6) for both Parts A and B
Number of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Time frame: End of study (up to Week 10)
Participants were enrolled at 70 investigative sites in the United States (US), Germany, and Poland from March 15, 2017 to June 27, 2019.
| Milestone | ALKS 8700 | Dimethyl Fumarate (DMF) |
|---|---|---|
| Started | 254 | 252 |
| Safety population | 253 | 251 |
| Completed | 245 | 233 |
| Not completed | 9 | 19 |
| Withdrew: Adverse event | 4 | 15 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Protocol deviation | 2 | 2 |
| Withdrew: Withdrawal by subject | 2 | 2 |
IGISIS assessed the intensity of five individual GI symptoms: nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea. Participants rated the intensity of each individual symptom via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). IGISIS was completed by the participants using e-diaries.
| days | ALKS 8700 | Dimethyl Fumarate (DMF) |
|---|---|---|
| Number of Days With Any Individual Gastrointestinal Symptom and Impact Scale (IGISIS) Individual Symptom Intensity Score ≥2 Relative to Exposure Days in Parts A and B | 1.5 ± 2.85 | 2.5 ± 4.68 |
IGISIS assessed the intensity of five individual GI symptoms: nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea. Participants rated the intensity of each individual symptom via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). IGISIS was completed by the participants using e-diaries.
| days | ALKS 8700 | Dimethyl Fumarate (DMF) |
|---|---|---|
| Number of Days With Any IGISIS Individual Symptom Intensity Score ≥2 Relative to Exposure Days in Part B | 1.3 ± 2.70 | 2.2 ± 4.22 |
IGISIS assessed the intensity of five individual GI symptoms: nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea. Participants rated the intensity of each individual symptom via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). IGISIS was completed by the participants using e-diaries.
| days | ALKS 8700 | Dimethyl Fumarate (DMF) |
|---|---|---|
| Number of Days With Any IGISIS Individual Symptom Intensity Score ≥1 Relative to Exposure Days in Parts A and B | 2.9 ± 4.46 | 3.9 ± 5.84 |
IGISIS assessed the intensity of five individual GI symptoms: nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea. Participants rated the intensity of each individual symptom via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). IGISIS was completed by the participants using e-diaries.
| days | ALKS 8700 | Dimethyl Fumarate (DMF) |
|---|---|---|
| Number of Days With Any IGISIS Individual Symptom Intensity Score ≥3 Relative to Exposure Days in Parts A and B | 0.9 ± 2.25 | 1.5 ± 3.85 |
GGISIS is a global scale to assess the overall intensity of GI symptoms (nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea). Participants rated the intensity of GI symptoms via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). GGISIS was completed by the participants using e-diaries.
| days | ALKS 8700 | Dimethyl Fumarate (DMF) |
|---|---|---|
| Number of Days With a Global GI Symptom and Impact Scale (GGISIS) Symptom Intensity Score ≥1 Relative to Exposure Days in Parts A and B | 2.1 ± 4.43 | 2.8 ± 5.19 |
GGISIS is a global scale to assess the overall intensity of GI symptoms (nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea). Participants rated the intensity of GI symptoms via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). GGISIS was completed by the participants using e-diaries.
| days | ALKS 8700 | Dimethyl Fumarate (DMF) |
|---|---|---|
| Number of Days With a GGISIS Symptom Intensity Score ≥2 Relative to Exposure Days in Parts A and B | 1.1 ± 3.25 | 1.5 ± 3.53 |
GGISIS is a global scale to assess the overall intensity of GI symptoms (nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea). Participants rated the intensity of GI symptoms via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). GGISIS was completed by the participants using e-diaries.
| days | ALKS 8700 | Dimethyl Fumarate (DMF) |
|---|---|---|
| Number of Days With a GGISIS Symptom Intensity Score ≥3 Relative to Exposure Days in Parts A and B | 0.7 ± 2.26 | 0.9 ± 2.57 |
IGISIS assessed the intensity of five individual GI symptoms: nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea. Participants rated the intensity of each individual symptom via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). IGISIS was completed by the participants using e-diaries. Scores were averaged for 5-week treatment period.
| score on a scale | ALKS 8700 | Dimethyl Fumarate (DMF) |
|---|---|---|
| Nausea | 0.9 ± 1.55 | 1.2 ± 1.98 |
| Vomiting | 0.2 ± 0.74 | 0.6 ± 1.84 |
| Upper Abdominal Pain | 0.8 ± 1.58 | 1.3 ± 2.06 |
| Lower Abdominal Pain | 0.8 ± 1.60 | 1.0 ± 1.84 |
| Diarrhea | 1.1 ± 2.09 | 1.3 ± 2.19 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
| participants | ALKS 8700 | Dimethyl Fumarate (DMF) |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 198 | 210 |
Collected over End of study (up to Week 10). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ALKS 8700 | 0/253 (0%) | 4/253 (1.6%) | 175/253 (69.2%) |
| Dimethyl Fumarate (DMF) | 0/251 (0%) | 3/251 (1.2%) | 191/251 (76.1%) |
| Event | ALKS 8700 | Dimethyl Fumarate (DMF) |
|---|---|---|
| Multiple sclerosis relapseNervous system disorders | 3/253 | 2/251 |
| CholecystitisHepatobiliary disorders | 0/253 | 1/251 |
| Atrial fibrillationCardiac disorders | 1/253 | 0/251 |
| Suicide attemptPsychiatric disorders | 1/253 | 0/251 |
| Event | ALKS 8700 | Dimethyl Fumarate (DMF) |
|---|---|---|
| FlushingVascular disorders | 83/253 | 102/251 |
| DiarrhoeaGastrointestinal disorders | 39/253 | 56/251 |
| NauseaGastrointestinal disorders | 37/253 | 52/251 |
| Abdominal pain upperGastrointestinal disorders | 17/253 | 39/251 |
| Abdominal painGastrointestinal disorders | 16/253 | 24/251 |
| VomitingGastrointestinal disorders | 9/253 | 22/251 |
| ErythemaSkin and subcutaneous tissue disorders | 20/253 | 21/251 |
| PruritusSkin and subcutaneous tissue disorders | 18/253 | 18/251 |
| Abdominal pain lowerGastrointestinal disorders | 15/253 | 17/251 |
| NasopharyngitisInfections and infestations | 15/253 | 11/251 |
The Safety population included all enrolled participants who had received at least one dose of study drug during the double-blind Treatment Period.
| Age, Continuous(years) | ALKS 8700 | Dimethyl Fumarate (DMF) | Total |
|---|---|---|---|
| Mean | 43.7 ± 10.96 | 43.7 ± 9.90 | 43.7 ± 10.44 |
| Sex: Female, Male(Participants) | ALKS 8700 | Dimethyl Fumarate (DMF) | Total |
|---|---|---|---|
| Female | 177 | 190 | 367 |
| Male | 76 | 61 | 137 |
| Race/Ethnicity, Customized(Participants) | ALKS 8700 | Dimethyl Fumarate (DMF) | Total |
|---|---|---|---|
| Not Hispanic or Latino | 248 | 241 | 489 |
| Hispanic or Latino | 5 | 10 | 15 |
| Race/Ethnicity, Customized(Participants) | ALKS 8700 | Dimethyl Fumarate (DMF) | Total |
|---|---|---|---|
| White | 232 | 227 | 459 |
| Black or African American | 20 | 20 | 40 |
| Other | 0 | 2 | 2 |
| Asian | 0 | 1 | 1 |
| Multiple races | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2017 to primary completion in Jun 2019, 27 months.
Results were first posted in Jul 2020, 1 year after primary completion.
Of 28 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 27 months is below that.
Counting every sponsor, half of 38 studies reached it within 48 months; a quarter within 27 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diroximel fumarate
Multiple Sclerosis, Relapsing-Remitting →